Elotuzumab, an immunostimulatory monoclonal antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7), showed activity in combination with lenalidomide and dexamethasone in a phase 1b-2 study in patients with relapsed or refractory multiple myeloma.
ultiple myeloma, a malignant disease of monoclonal plasma cells, has a median overall survival of approximately 5 years. 1 Despite improvements in treatment outcomes with proteasome inhibitors and immunomodulatory drugs, most patients continue to have a relapse, and new treatment approaches are needed. Combination therapy may be key to overcoming drug resistance and improving long-term treatment outcomes. Lenalidomide, an immunomodulatory drug, in combination with dexamethasone is a standard regimen in patients with relapsed or refractory disease. 2, 3 Three-drug combinations are emerging for patients with previously treated multiple myeloma 3 but may be limited by toxic effects. Agents with new mechanisms of action that can be combined with existing therapies without an increase in serious toxicity are needed.
Elotuzumab is a first-in-class humanized immunoglobulin G1 immunostimulatory monoclonal antibody targeted against signaling lymphocytic activation molecule F7 (SLAMF7, also called CS1 [cell-surface glycoprotein CD2 subset 1]), a glycoprotein expressed on myeloma and natural killer cells but not on normal tissues that enables selective killing of myeloma cells with minimal effects on healthy tissue. 4 The SLAM family is a subgroup of the immunoglobulin superfamily of receptors and consists of six members (SLAM, 2B4, Ly-9, NTB-A, CD94, and SLAMF7), all located on chromosome 1q23. 5 More than 95% of bone marrow myeloma cells express SLAMF7 in a manner that is independent of cytogenetic abnormalities. 4, 6 Elotuzumab exerts a dual effect by directly activating natural killer cells and mediating antibody-dependent cell-mediated cytotoxicity through the CD16 pathway. 7 SLAMF7 mediates activating signals in natural killer cells by coupling with its adapter protein EAT-2. In myeloma cells, SLAMF7 signaling is compromised owing in part to the lack of EAT-2 expression; therefore, elotuzumab does not induce the proliferation of myeloma cells. 8, 9 In a single-group, phase 2 trial of elotuzumab in combination with lenalidomide and dexamethasone (Study 1703), this immunostimulatory activity translated into an improvement in progression-free survival in patients with relapsed or refractory multiple myeloma. 10 The objective of this randomized, phase 3 trial, called ELOQUENT-2, was to evaluate the efficacy and safety of elotuzumab in combination with lenalidomide and dexamethasone, as compared with lenalidomide and dexamethasone alone, in patients with relapsed or refractory multiple myeloma. We report the results of the final analysis of the primary end points, performed after a minimum follow-up of 2 years and the occurrence of at least 70% of required events.
Me thods

Study Design and Oversight
This open-label, multicenter trial received approval from the institutional review board or independent ethics committee at each study site before initiation. Written informed consent was obtained from all patients. The study was designed jointly by the sponsors (Bristol-Myers Squibb and AbbVie Biotherapeutics) and the investigators. The sponsors were responsible for the collection and maintenance of the data. All the authors had input into manuscript development at all stages and approved the manuscript before submission. The authors made the decision to submit the manuscript for publication and vouch for the adherence to the study protocol and for the accuracy and completeness of the reported data. Professional medical writers who were paid by Bristol-Myers Squibb contributed to the preparation of the manuscript and are not listed as authors. The protocol and statistical analysis plan are available with the full text of this article at NEJM.org.
Patients
Eligible patients were 18 years of age or older and had multiple myeloma and measurable disease. All patients had received one to three previous therapies and had documented disease progression after their most recent therapy. All patients had a creatinine clearance of 30 ml per minute or higher. Previous treatment with lenalidomide was permitted, subject to restrictions (see the Supplementary Appendix, available at NEJM.org).
Randomization and Study Treatment
Eligible patients were randomly assigned in a 1:1 ratio to receive either elotuzumab in combination with lenalidomide and dexamethasone (elotuzumab group) or lenalidomide and dexamethasone alone (control group) in 28-day cycles until disease progression, unacceptable toxicity, or withdrawal of consent ( Patients received mandatory premedication before elotuzumab infusion along with thromboembolic prophylaxis. The premedication regimen -consisting of diphenhydramine (25 to 50 mg) or its equivalent, ranitidine (50 mg) or its equivalent, and acetaminophen (650 to 1000 mg) or its equivalent -was administered 30 to 90 minutes before the elotuzumab infusion. Thromboembolic prophylaxis (e.g., aspirin, low-molecular-weight heparin, or vitamin K antagonists) was administered according to institutional guidelines or at the discretion of the investigator.
Randomization was stratified according to the baseline β 2 -microglobulin level (<3.5 mg per liter vs. ≥3.5 mg per liter), the number of previous therapies (one vs. two or three), and previous immunomodulatory drug therapy (none vs. thalidomide only or other) (see the Supplementary Appendix). In total, a maximum of 10% of patients who had received previous lenalidomide therapy could enroll.
Study End Points
The coprimary end points were progression-free survival and the overall response rate (partial response or better). Key secondary end points were overall survival and the severity of pain or interference with daily life. Exploratory end points that are reported here are the time to tumor response, duration of response, health-related quality of life, and safety. The trial will continue until the final overall survival end point of 427 deaths.
Assessments
Efficacy end points were centrally assessed on the basis of the criteria of the European Group for Blood and Marrow Transplantation (see the Supplementary Appendix) and on a blinded review of tumor assessments by an independent review committee. Tumor assessments were performed every 4 weeks after the first dose of study medication until disease progression, death, or withdrawal of consent (see the Supplementary Appendix). The uniform response criteria of the International Myeloma Working Group (see the Supplementary Appendix) were incorporated into the assessment of the independent review committee for the evaluation of stringent complete response and very good partial response. Pain and health-related quality of life were assessed with the use of the Brief Pain InventoryShort Form and the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire-Core 30 module (EORTC QLQ-C30) and myeloma-specific module (EORTC QLQ-MY20) (see the Supplementary Appendix).
Statistical Analysis
The two-sided type I error rates for the coprimary end points (progression-free survival and overall response rate) were 4.5% and 0.5%, respectively. We determined that 640 patients with 466 events would provide a power of 89% to detect a hazard ratio of 0.74 for disease progression or death in the elotuzumab group in the final analysis. This interim analysis was scheduled to be performed when at least 70% of the required events had been observed and after a minimum follow-up of 2 years. The alpha level for the analysis of progression-free survival (0.0239) was calculated on the basis of the occurrence of 384 of 466 events (82%) at the time of the interim analysis. An observed hazard ratio of 0.794 or less for disease progression or death indicated a statistically significant difference.
In the primary analysis of progression-free survival, we used the assessment of tumor response by the independent review committee and the primary definition of progression-free survival, for which censoring rules were applied to data for patients who received subsequent antimyeloma therapy or missed assessments (see the Supplementary Appendix). Supportive analyses for progression-free survival used the intention-totreat definition of progression-free survival, for which no censoring was applied for subsequent therapy or missing assessments (see the Supple- (Fig. 1A) .
In the elotuzumab group, 179 events were observed (165 progressions and 14 deaths), and in the control group, 205 events were observed (183 progressions and 22 deaths). The benefit for progression-free survival in the elotuzumab group was consistent across key subgroups, including patients 65 years of age or older and those with resistance to the most recent line of therapy, with International Staging System stage III disease, with previous exposure to bortezomib or immunomodulatory drugs, with previous stemcell transplantation, with the del(17p) variant, or with a creatinine clearance of less than 60 ml per minute (Fig. 1B) .
The benefit was also consistent across supportive analyses of progression-free survival. In the intention-to-treat population, there was a relative reduction of 32% in the risk of progressionfree survival in the elotuzumab group (hazard ratio, 0.68; 95% CI, 0.56 to 0.83) ( Table S2 in the Supplementary Appendix). Multivariate analysis suggested that the greatest benefit in progressionfree survival occurred among patients in whom multiple myeloma had been diagnosed 3.5 years or more before study entry (hazard ratio, 0.55; 95% CI, 0.44 to 0.70; P<0.001), with a median survival of 26.0 months in the elotuzumab group versus 17.3 months in the control group.
The study also met the prespecified statistical cutoff for the coprimary end point of overall response rate. Overall response rates were 79% (95% CI, 74 to 83) in the elotuzumab group and 66% (95% CI, 60 to 71) in the control group (odds ratio for the elotuzumab group versus the control group, 1.9; 95% CI, 1.4 to 2.8; P<0.001) ( Table 2 ). In the analysis by the independent review committee, there were fewer complete responses in the elotuzumab group than in the control group. In the two study groups, the median time to best response was 2.8 months according to independent review and 3.8 months according to investigator assessment. In supportive analyses that used investigator-assessed tumor responses, the rates of complete responses were similar (11% in each group) ( Table S3 in the Supplementary Appendix). Furthermore, 105 of 321 patients (33%) in the elotuzumab group had a very good partial response or better, versus 91 of 325 patients (28%) in the control group. Patients in the elotuzumab group who had a partial response or better had better progression-free survival outcomes than did those with a minor response or stable disease (Fig. S3  in Overall, there was no significant difference in the change from baseline in pain severity (P = 0.87) and pain interference (P = 0.81) between the elotuzumab group and the control group. EORTC QLQ-C30 findings showed that pain and fatigue were the symptoms with the highest baseline values reported by patients. There was no significant detriment to overall health-related quality of life with the addition of elotuzumab to lenalidomide and dexamethasone; similar mean changes * Cytogenetic analysis was performed at the screening visit at a central laboratory with the use of karyotyping and fluorescence in situ hybridization. There was no cutoff for del(17p) positivity; if any cell in the analyzed sample was positive for the mutation, the patient was considered to be del(17p) positive. † The International Staging System (ISS) is based on serum levels of β 2 -microglobulin and albumin as follows: stage I, β 2 -microglobulin level of less than 3.5 mg per liter and albumin level of 3.5 g per deciliter or more; stage II, β 2 -microglobulin level of 3.5 to less than 5.5 mg per liter or albumin level of less than 3.5 g per deciliter if the β 2 -microglobulin level is less than 3.5 mg per liter; and stage III, β 2 -microglobulin level of 5.5 mg per liter or more. ‡ Owing to a protocol deviation, one patient in each group had received four previous regimens. (170) 85 (155) 85 (150) 9 (16) 132 (219) 47 (102) 9 (16) 170 (305) 102 (167) 77 (154) 50 (102) 88 (147) 21 (30) 53 (96) 126 (225) 87 (142) 118 (183) 107 (179) 98 (146) 80 (138) 67 (105) 50 (68) 77 (114) 128 (211) 101 (159) 104 (166) 91 (151) 101 (153) 13 (21) 150 (231) 55 (94) 13 (21) 192 (304) 117 (185) 88 (140) 61 (104) 105 (163) 25 (31) 55 (75) 150 (250) 
no. of events (total no. of patients)
Hazard from baseline were observed in the two groups, and patients receiving elotuzumab were able to maintain their overall health-related quality of life.
Safety
A total of 635 patients were treated. The median duration of treatment was 17 months in the elotuzumab group and 12 months in the control group; 65% and 79% of patients, respectively, discontinued treatment, most commonly owing to disease progression (Fig. S2 in the Supplementary Appendix). Adverse events that were reported in 25% or more of patients in either study group are shown in Table 3 . Serious adverse events were reported in 65% and 57% of patients in the elotuzumab group and the control group, respectively. In the elotuzumab group, 34% of patients had grade 3 or 4 neutropenia, as compared with 44% in the control group; grade 3 or 4 lymphocytopenia was reported in 77% and 49% of patients, respectively. The mean percentage change from baseline in the absolute lymphocyte count is shown in Figure S5 in the Supplementary Appendix. Rates were similar between groups for grade 3 or 4 cardiac disorders, with 4% in the elotuzumab group and 6% in the control group, and for renal disorders, with 4% in each group. In the elotuzumab group, infections were reported in 81% of patients versus 74% in the control group. After adjustment for drug exposure, rates of infection were equal in the two groups (197 events per 100 patient-years). The rate of herpes zoster infection was greater in the elotuzumab group than in the control group (incidence per 100 patient-years, 4.1 vs. 2.2); 1 patient in the control group discontinued treatment because of herpes zoster infection. Other than herpes zoster, there was no increase in the incidence of opportunistic infections.
A similar proportion of patients in each study group (2%) died from an adverse event. In the elotuzumab group, 2 patients died from infections and 1 each from pulmonary embolism, gastrointestinal cancer, and the myelodysplastic syndrome. In the control group, 5 patients died from infections and 1 from pulmonary embolism.
Infusion reactions, including pyrexia, chills, and hypertension, were reported in 33 patients (10%) receiving elotuzumab; such reactions were grade 1 or 2 in 29 patients, and no patient had a grade 4 or 5 reaction. Most infusion reactions (70%) occurred with the first dose of study therapy. Elotuzumab infusion was interrupted in 15 patients (5%) for a median of 25 minutes (range, 5 to 70, with 18 interruptions). Infusion reactions resolved in all except 2 patients (1%) who discontinued treatment because of an infusion reaction.
Of the 299 patients in the elotuzumab group who had been tested for the presence of antidrug antibodies, 6 patients (2%) had positive results before starting therapy. During elotuzumab treatment, 254 patients (85%) had negative results on testing for antidrug antibodies throughout treatment, 45 patients (15%) had positive results on at least one occasion, and 2 patients (1%) had positive results on more than two consecutive occasions.
Discussion
In patients with relapsed or refractory multiple myeloma, the addition of elotuzumab to lenalidomide and dexamethasone, as compared with lenalidomide and dexamethasone as control therapy, improved progression-free survival and the overall response rate, showing that direct activation and engagement of the innate immune system to selectively kill myeloma cells can provide clinically meaningful and statistically significant improvements in treatment outcomes. Specifically, Kaplan-Meier curves for progressionfree survival showed early and increasing separation between the two groups over time. Patients receiving elotuzumab had a relative reduction of n engl j med nejm.org
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T h e ne w e ngl a nd jou r na l o f m e dicine 30% in the risk of disease progression or death as compared with the control group. Follow-up for survival outcomes is ongoing. The benefit of adding elotuzumab to lenalidomide and dexamethasone was observed across most prespecified subgroups, including patients with resistance to the most recent line of therapy and those who had previous exposure to immunomodulatory drugs or bortezomib, were 65 years of age or older, had received a diagnosis of multiple myeloma at least 3.5 years before study entry, or had a high-risk cytogenetic profile, particularly the presence of the del(17p) variant. The benefit with respect to progression-free survival was further confirmed by means of multiple sensitivity analyses.
There was an absolute difference of 13 percentage points in the overall response rate in favor of the elotuzumab group. Fewer complete responses were observed in the elotuzumab group than in the control group, although the rate of complete response may have been underestimated owing to the detection of therapeutic antibody on serum protein electrophoresis and immunofixation assays, as has been shown in trials of daratumumab, siltuximab, and ofatumumab. [11] [12] [13] Strategies are being planned to mitigate such interference in future studies. The addition of elotuzumab to lenalidomide and dexamethasone had no significant effect on patients' pain or health-related quality of life, despite being a three-drug regimen that included an intravenous drug and a premedication regimen.
Differences in patient populations and treatment history make cross-trial comparisons challenging. Progression-free survival in the phase 2 portion of the phase 1b-2 study of elotuzumab plus lenalidomide and dexamethasone was 29 months, 10 versus 21 months for investigatordetermined progression-free survival in our study. However, patients in the earlier study were younger (median age, 63 years) and fewer had a high-risk cytogenetic profile, 10 whereas there were more patients with coexisting illnesses in the study population described here. In the intention-to-treat analysis, the elotuzumab groups had treatment benefits that were similar to those reported in other phase 3 studies. 14 Could not be evaluated 9 (3) 17 (5) * The listed treatment responses were determined by the independent review committee. The uniform response criteria of the International Myeloma Working Group were incorporated into the assessment of the stringent complete response and very good partial response. CI denotes confidence interval, CR complete response, sCR stringent complete response, and VGPR very good partial response. † The overall response was defined as partial response or better on the basis of the criteria of the European Group for Blood and Marrow Transplantation. The odds ratio for an overall response in the elotuzumab group was 1.9 (95% CI, 1.4 to 2.8; P<0.001 by the Cochran-Mantel-Haenszel chi-square test stratified according to randomization factors). ‡ Complete response rates in the elotuzumab group may be underestimated owing to interference from the presence of therapeutic antibody in results on immunofixation and serum protein electrophoresis assays. difference in median progression-free survival among patients receiving elotuzumab in our study and in other studies involving patients with multiple myeloma may reflect disparate study populations. For example, in our study, 20% of the patients were 75 years of age or older. Although few patients in our study had received previous lenalidomide treatment, more than one third of patients had resistance to previous therapy, including bortezomib or thalidomide. In addition, as noted above, our study had a high proportion of patients (30%) who had a high-risk cytogenetic profile, when defined as positive results on testing for t(4;14) or t(14;16) or at least 60% cells with del(17p). Elotuzumab in combination with lenalidomide and dexamethasone produced modest incremental adverse events in a population in which more than half of patients were 65 years of age or older. Lymphocytopenia was observed in elotuzumab-treated patients, which may reflect alterations in lymphocyte trafficking, in- 
